Search Medical Condition
Please enter condition
Please choose location
 

Bellaie, Texas Clinical Trials

A listing of Bellaie, Texas clinical trials actively recruiting patient volunteers.

RESULTS

Found (2282) clinical trials

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

Patients will be admitted to the surgical center on the day of their abdominal surgery (Day 1, unless admission the night before is required). All patients will be seen by the study staff to confirm eligibility, review study procedures, and conduct all pre-surgical assessments required for randomization. Qualified patients will ...

Phase

0.0 miles

Learn More »

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

Study is conducted in 2 parts: part A and part B. Part A - Patients with moderate-to-severe AD will be randomized to receive dupilumab (dose 1) by auto-injector (AI) device or prefilled syringe. Once part A is completely enrolled, part B will randomize patients with moderate-to-severe AD to receive dupilumab ...

Phase

0.28 miles

Learn More »

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

Phase

0.28 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream 1% in Subjects With Facial Acne Vulgaris (25)

The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

Phase

0.28 miles

Learn More »

Medigus Ultrasonic Surgical Endostapler (MUSE) Registry

The registry evaluates the MUSE System which creates a transoral anterior fundoplication for the treatment of GERD. The system enables the operator to staple the fundus of the stomach to the esophagus approximately 3cm superior to the Z-line in 2 or more locations. The procedure is performed transorally under general ...

Phase N/A

0.28 miles

Learn More »

ING200336 Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection

In this study, the dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) tablet is being made available to women who become pregnant while participating in study ING117172. Continuation of antiretroviral therapy (ART) is key to both mother and the unborn fetus in order to maintain virologic suppression in the mother (thereby decreasing ...

Phase

0.28 miles

Learn More »

Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

This is a Phase 2b, randomized, double-blind, saline placebo- and active-controlled, multicenter study in subjects undergoing primary unilateral total knee arthroplasty (TKA) to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 administered via infiltration to the surgical site.

Phase

0.28 miles

Learn More »

Long-term Observational Study in HIV Subjects Exposed to EGRIFTA

The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA.

Phase N/A

0.28 miles

Learn More »

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA

To date, EGRIFTA has not been studied for longer than 1 year in human subjects, nor has EGRIFTA been studied in Type 2 diabetic HIV-infected subjects who are receiving oral hypoglycemic agents, GLP-1 analogues, or insulin. The present study will assess the potential of EGRIFTA to induce or exacerbate DR ...

Phase

0.28 miles

Learn More »

Efficacy Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS-2M) study is designed to demonstrate the non-inferior antiviral activity and safety of CAB LA + RPV LA administered every 8 weeks (Q8W) compared to CAB LA + RPV LA administered every 4 weeks (Q4W) over a 48-week treatment period ...

Phase

0.28 miles

Learn More »